Figure 6 | Scientific Reports

Figure 6

From: Transcriptomic changes underlying EGFR inhibitor resistance in human and mouse models of basal-like breast cancer

Figure 6

(A–F) Representative images of immunohistochemical staining for LCN2 on formalin-fixed, paraffin-embedded WHIM2 parental and WHIM2 Erl/R mammary gland tumors; (G) Quantification of LCN2-negative cells and LCN2-positive cells in each image; (H) Percentage of total cells in the image that were LCN2-positive (P = 0.021). (I) Western blot of lysates from LCN2 siRNA and non-targeting siRNA transfected WHIM2 erlotinib-resistant PDX cells. (J) Erlotinib treatment on WHIM2 erlotinib-resistant PDX cells with LCN2 siRNA or non-targeting siRNA transfection (P < 0.05 at 5 μM, P < 0.001 at 7 μM and 9 μM).

Back to article page